期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

去铁酮 被引量：2

deferiprone
原文传递
导出
摘要 FDA于2011年10月14日批准了加拿大ApoPharma公司开发的去铁酮（deferiprone,商品名为奥贝安可,Fer-riprox）在美国上市,该药用于治疗对既往螯合治疗反应不佳的以及由于输血导致铁负荷过多的地中海贫血^[1]。去铁酮的中文化学名称为：3-羟基-1,2-二甲基-4-（1H）-吡啶酮：英文化学名称为：3．hvdroxv-1．2．dimeth-ylpyridin-4（1H）-one；分子式：C7H9NO2；分子量：139．152；CAS登记号：30652-11-0。 The synthesis and spectroscopic characterization of a series of nbutyl (βtrichlorostannyl)propionate complexes with bidentate nitrogen ligands 2,2′bipyridine,1,10phenanthroline and its derivatives are described in this paper.Their IR and proton NMR spectra are discussed.The in vitro antitumour activities of some of these complexes tested against Ehrlich ascites tumour,P388 lymphocytic leukaemia and SGC7901 gastroadenocarcinoma are higher than that of aclacinomycin A of cisplatin.
作者 毕春雨（编译） 胡春（审校）
机构地区 沈阳药科大学
出处 《中国药物化学杂志》 CAS CSCD 2012年第2期174-174,共1页 Chinese Journal of Medicinal Chemistry
关键词 去铁酮 Pharma公司 治疗反应 化学名称 地中海贫血 铁负荷过多 APO 加拿大 organotin complexes synthesis IR spectra proton NMR spectra antitumour activity
分类号 R973.3 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1周敦华,方建培.珠蛋白生成障碍性贫血的铁螯合剂治疗[J].实用儿科临床杂志,2009,24(3):167-170. 被引量：3
  • 2李晓.铁螯合剂治疗的新进展[J].世界临床药物,2007,28(8):479-481. 被引量：6
  • 3US FDA.FDA approves ferriprox to treat patients with excess i-ron in the body. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 275814.htm . 2011
  • 4HARRIS RLN.Potential wool growth inhibitors.Improved syn-theses of mimosine and related4 (1H)-pyridones[].Australian Journal of Chemistry.1976
  • 5Dobbin PS,Hider RC,Hall AD,et al.Synthesis,physicochemical properties, and biological evaluation of N -substituted-2-alkyl -3-hydroxy-4 ( 1H )-pyridinones: orally active iron chelators with clinical potential[].Journal of Medicinal Chemistry.1993
  • 6Teresa Cablewski,Alan F Faux,Christopher R. Strauss.Development and Application of a Continuous Microwave Reactor for Organic Synthesis[].Journal of Organic Chemistry.1994
  • 7Raymond C Fox,,Paul D. Taylor.Efficient synthesis of N-alkyl-3-hydroxy-2-methyl-4(1H)-pyridinones from carbohydrate precursors[].Synthesis communications.1999

二级参考文献26

  • 1Modell B, Khan M, Darlison M. Survival in beta - thalassemia major in the UK : Data from the UK Thalassemia Register [ J ]. Lacent, 2000,355 (9220) :2051 - 2052.
  • 2Chan YL, Li CK, Pang LM, et al. Desferrioxamine - induced long bone changes in thalassemia patients - radiographic features, prevalence and relations with growth [ J ]. Clin Radiol,2000,55 ( 8 ) :610 - 614.
  • 3Gabutti V, Piga A. Results of long term iron -chelating therapy [ J ]. Acta Haematol, 1996,95 ( 1 ) :26 - 36.
  • 4Kattamis A, Dinopoulos A, Ladis V, et al. Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients [ J ]. Am J Heamatol, 2001,68 ( 4 ) : 221 - 224.
  • 5Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation [ J ]. J Cardiovasc Magn Resort,2006,8 ( 3 ) : 543 - 547.
  • 6Caro J,Huybrenehts KF,Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron over load in thalassemia major: A systematic review [ J]. BMC Blood Disord,2002,2( 1 ) :4.
  • 7Pennell D J, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta - thalassemia major patients with asymptomatic myocardial siderosis [ J ]. Blood, 2006, 107 ( 9 ) : 3738 -3744.
  • 8Borgna - Pignatti C, Cappellini MD, de Stefano P, et al. Cardiac morbidity and mortality in deferoxamine - or deferiprone - treated patients with thalassemia major[ J ]. Blood ,2006,107 ( 9 ) :3733 - 3737.
  • 9Lesic B, Foulon J, Carniel E, et al. Comparision of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica[ J ]. Antimicrob Agents Chemother, 2002,46 ( 6 ) : 1741 - 1745.
  • 10Brener W, Ermers M J, Pootrakul P, et al. Desferrioxamine - chelatable iron, a component of serum non - transferrin - bound iron, used for assessing chelation therapy[ J ]. Blood,2001,97 ( 3 ) :792 - 798.

共引文献7

同被引文献22

  • 1李晶媛,李树臣,杨维良.TNF-α诱导肝细胞凋亡机制的回顾与展望[J].世界华人消化杂志,2007,15(6):606-611. 被引量：27
  • 2WALBOOMERS J M M, JACOBS M V, MANOS M M, et al.Human papillomavirus is a necessary cause of invasive cervi-cal cancer worldwide[J]. The Journal of Pathology, 1999, 189(1):12-19.
  • 3LI J, KANG L N, QIAO Y L, Review of the cervical cancerdisease burden in China's Mainland[J]. Asian Pacific Journal ofCancer Prevention, 2011, 12(5): 1149-1153.
  • 4SHENKIN A. Basics in clinical nutrition: physiological func-tion and deficiency states of trace elements[J]. e-SPEN the Eu-ropean e-Journal of Clinical Nutrition and Metabolism, 2008,3(6): e255-e258.
  • 5PAPADAKI C, TRYPAKI M, KOUTSOPOULOS A, et al. As-sociation of tumoral BRCA1, RRM1 and RRM2 mRNA expres-sion levels with clinical responses to front-line docetaxel/gem-citabine (DG) chemotherapy in patients with non-small cell lungcancer (NSCLC)[J]. Journal of Clinical Oncology, 2008, 26(15):431-436.
  • 6BYUN D S, CHAE K S, RYU B K, et al. Expression and muta-tion analyses of P53R2, a newly identified p53 target for DNArepair in human gastric carcinoma[J]. International Journal ofCancer, 2002, 98(5): 718-723.
  • 7LE N T, RICHARDSON D R. The role of iron in cell cycleprogression and the proliferation of neoplastic cells[Jl. Biochim-ica et Biophysica Acta, 2002, 1603(1): 31-46.
  • 8STEVENS R G, GRAUBARD B I, MICOZZI M S, et al. Mode-rate elevation of body iron level and increased risk of canceroccurrence and death[J]. International Journal of Cancer, 1994,56(3): 364-369.
  • 9RICHARDSON D R. Iron chelators as therapeutic agents forthe treatment of cancer[J]. Critical Reviews in Oncology/Hema-tology, 2002,42(3): 267-281.
  • 10SIMONART T, BOELAERT J R, MOSSELMANS R, et al. An-tiproliferative and apoptotic effects of iron chelators on humancervical carcinoma cells[J]. Gynecologic Oncology, 2002, 85(1):95-102.

引证文献2

中国药物化学杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部